Latest Ratios: P/E Ratio -1.4x · EV/EBITDA N/A · ROE N/A. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $89M | $159M | — | — | — | — |
| Enterprise Value | $95M | $165M | — | — | — | — |
| P/E Ratio → | -1.37 | — | — | — | — | — |
| P/S Ratio | 2215.00 | 3973.02 | — | — | — | — |
| P/B Ratio | — | — | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 4129.44 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating Margin | -145459.4% | -145459.4% | -8605.4% | -17311.0% | -14188.0% | — |
| Net Profit Margin | -155404.4% | -155404.4% | -14335.5% | -21176.0% | -15233.8% | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — |
| ROA | -2200.9% | -2200.9% | -508.2% | -1496.6% | -800.5% | -10389.3% |
| ROIC | — | — | — | — | — | — |
| ROCE | — | — | — | — | — | — |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -23.81 | -23.81 | -2.64 | -4.48 | -14.18 | -28.97 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 0.07 | 0.07 | 0.25 | 0.08 | 0.32 | 0.01 |
| Quick Ratio | 0.07 | 0.07 | 0.25 | 0.08 | 0.32 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.01 | 0.00 | 0.27 | 0.01 |
| Asset Turnover | — | 0.01 | 0.02 | 0.06 | 0.03 | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | 653.94 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $19M | $19M | $19M | $19M | $19M |
Imminent liquidity exhaustion risk
As reported in financial statements, NTHI trades at a P/S ratio of 2255.00, a figure that appears untethered from fundamental performance and instead reflects a high-risk, lottery-ticket valuation typical of early-stage biotechnology firms lacking any meaningful commercial revenue or established product market fit.
The extreme P/S multiple suggests that investors are pricing the company entirely on the potential success of its Phase 2a clinical trials rather than any current operational metrics. This valuation level warrants extreme caution, as it implies an expectation of significant future breakthroughs that may not materialize given the company's current liquidity constraints.
Based on NTHI's reported figures, the current ratio has deteriorated to a precarious 0.08 as of 2026Q1, indicating that the firm lacks the liquid assets necessary to satisfy its immediate short-term obligations without a rapid and substantial infusion of external capital.
The consistent decline in the current ratio over the observed quarters highlights a deepening liquidity crisis that threatens the company's ability to continue as a going concern. Investors should monitor the firm's ability to secure financing, as the current cash position appears insufficient to sustain ongoing clinical development activities.
According to recent SEC filings, NTHI's asset turnover remains effectively at zero, reflecting the company's pre-commercial status and the absence of any revenue-generating assets that could contribute to operational efficiency or meaningful working capital management at this stage of development.
The lack of asset turnover confirms that the company is currently an R&D vehicle rather than an operational business. The absence of meaningful working capital metrics further underscores the firm's reliance on external funding to cover its high fixed-cost structure.
As evidenced by the provided data, the use of gross margin as a performance indicator for NTHI is fundamentally flawed, as the reported 100% margin is a mathematical artifact of zero revenue rather than a reflection of superior pricing power or operational efficiency.
Analysts frequently misapply traditional profitability ratios to pre-revenue biotech firms, which obscures the reality of their cash-burning business models. Instead of gross margin, investors should focus on the 'burn rate' and 'time to exhaustion' to better understand the company's financial viability.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NTHI stock.
Neonc Technologies Holdings, Inc.'s current P/E ratio is -1.4x. This places it at the 50th percentile of its historical range.
Based on historical data, Neonc Technologies Holdings, Inc. is trading at a P/E of -1.4x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Neonc Technologies Holdings, Inc. has 100.0% gross margin and -145459.4% operating margin.